Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Shin Nippon Biomedical Laboratories's Days Sales Outstanding or its related term are showing as below:
SBLOF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 52.95 Med: 64.68 Max: 78.26
Current: 67.59
During the past 13 years, Shin Nippon Biomedical Laboratories's highest Days Sales Outstanding was 78.26. The lowest was 52.95. And the median was 64.68.
SBLOF's Days Sales Outstanding is ranked better than 50.75% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.79
vs SBLOF: 67.59
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shin Nippon Biomedical Laboratories Days Sales Outstanding Chart
SBLOF vs TMO, DHR, IDXX: Days Sales Outstanding Comparison
For the Diagnostics & Research subindustry, Shin Nippon Biomedical Laboratories's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shin Nippon Biomedical Laboratories Days Sales Outstanding vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Shin Nippon Biomedical Laboratories's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Shin Nippon Biomedical Laboratories's Days Sales Outstanding falls into.
Shin Nippon Biomedical Laboratories Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shin Nippon Biomedical Laboratories (SBLOF) has a Days Sales Outstanding of 50.26 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Shin Nippon Biomedical Laboratories and its competitors. This is 22% below median its historical median of 64.68. Over the past decade, Shin Nippon Biomedical Laboratories' Days Sales Outstanding has ranged from 52.95 to 78.26. According to the industry distribution chart, Shin Nippon Biomedical Laboratories ranks #99 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 49.3%.
Is Shin Nippon Biomedical Laboratories' Days Sales Outstanding too high?
Shin Nippon Biomedical Laboratories' current Days Sales Outstanding of 50.26 is 22% below median its 10-year median of 64.68. Over the past 10 years, this metric has ranged from a low of 52.95 to a high of 78.26. The Medical Diagnostics & Research industry median Days Sales Outstanding is 67.79. Shin Nippon Biomedical Laboratories' value of 50.26 is 25.9% below this industry median. Based on the distribution chart, Shin Nippon Biomedical Laboratories ranks #99 out of 201 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Shin Nippon Biomedical Laboratories has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Shin Nippon Biomedical Laboratories' Days Sales Outstanding compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Shin Nippon Biomedical Laboratories ranks #99 out of 201 companies for Days Sales Outstanding. This puts Shin Nippon Biomedical Laboratories in the upper half of its industry. The industry median Days Sales Outstanding is 67.79. Shin Nippon Biomedical Laboratories' value of 50.26 is 25.9% below this benchmark. Historically, Shin Nippon Biomedical Laboratories' own Days Sales Outstanding has ranged from 52.95 to 78.26 over the past decade. While the company's 10-year median is 64.68 vs. the industry median of 67.79, Shin Nippon Biomedical Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Diagnostics & Research company?
The median Days Sales Outstanding among Medical Diagnostics & Research companies is 67.79, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shin Nippon Biomedical Laboratories's current Days Sales Outstanding of 50.26 is 25.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Shin Nippon Biomedical Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median Days Sales Outstanding is 67.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shin Nippon Biomedical Laboratories's current Days Sales Outstanding is 50.26, which is 22% below median its own 10-year median of 64.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shin Nippon Biomedical Laboratories stock overvalued right now?
Shin Nippon Biomedical Laboratories (SBLOF) has a current Days Sales Outstanding of 50.26. The stock's GF Value™ is $11.70, compared to a current price of $9.16 — trading 21.7% below its estimated fair value. The current Days Sales Outstanding is 50.26, which is 22% below median its 10-year median of 64.68 and 25.9% below the Medical Diagnostics & Research industry median of 67.79. Shin Nippon Biomedical Laboratories' overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Shin Nippon Biomedical Laboratories (SBLOF), the current Days Sales Outstanding is 50.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shin Nippon Biomedical Laboratories (SBLOF) Overvalued in 2026?
Based on GuruFocus' analysis, Shin Nippon Biomedical Laboratories stock appears to be undervalued.
The current stock price of $9.16 is trading 21.7% below its estimated GF Value™ of $11.70.
Key valuation signals for SBLOF:
Days Sales Outstanding: 50.26 (22% below median its 10-year median of 64.68)
GF Value™: $11.70 vs. price of $9.16 (21.7% below fair value)
Industry Position: 25.9% below the Medical Diagnostics & Research median (#99 of 201)
No single metric tells the full story. See the SBLOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.
78GF Score
Get the complete analysis for SBLOF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBLOF has been successfully added to your 
